Pharming « Terug naar discussie overzicht

quote:

Madebeliefje schreef op 15 februari 2018 13:04:

Hoezo ineens kelderen???

quote:

C200 schreef op 15 februari 2018 13:05:

[...]
Haha we zijn alweer terug. Korte spike down

quote:

Derealiteit schreef op 15 februari 2018 13:26:

The global hereditary angioedema market was valued at US$ 1,750.2 Million in 2016, and is expected to reach US$ 3,689.4 Million by 2025 expanding at a CAGR of 8.19% from 2017 to 2025.

In 2016, C1 esterase inhibitors segment dominated the market due to the recent approval of novel drugs: Berinert and Haegarda. Additionally, technological advancement in drug delivery (for e.g. Haegarda is the only medication available as a subcutaneous treatment option).

Kallikrein inhibitors is expected to be the fastest growing segment throughout the forecast period 2017-2025, majorly due to increasing incidences in patients with severe angioedema anaphylactic shock and promising product pipeline, touted to offer better results than the existing treatment options.

quote:

Madebeliefje schreef op 15 februari 2018 13:34:

[...]

Welke mafkees schrijft dit als dit de waarschuwing is voor Kalbitor:

WARNING: ANAPHYLAXIS
Anaphylaxis has been reported after administration of Kalbitor. Because of the risk of anaphylaxis, Kalbitor should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. Do not administer Kalbitor to patients with known clinical hypersensitivity to Kalbitor.

Echt waar, men lult maar wat overal zonder enig benul te hebben.(Niet tegen de poster gericht, maar tegen degene die dit soort zaken in de krant/internet plaatst)

quote:

Deneus schreef op 15 februari 2018 13:41:

staat zelfs op hun site volgens mij.